Emcure Pharmaceuticals Q2 FY27 Earnings Call Transcript Released
Emcure Pharmaceuticals reported a strong Q2 FY27 with revenue up 24% YoY to ₹2,820 crore and PAT up 29% to ₹325 crore. International business grew 34.5% to ₹1,665 crore, forming 59% of revenue. The company raised its FY27 revenue growth outlook to over 20% and expects EBITDA margin improvement. Key growth drivers include domestic portfolios and international expansion.
The announcement details significant financial performance improvements, a raised revenue growth outlook, and a clear path towards becoming net cash. These positive financial indicators and strategic updates are likely to have a substantial impact on investor perception and the company's stock.
The company reported strong year-on-year growth in revenue, EBITDA, and profit after tax, exceeding expectations and raising its full-year guidance. Positive commentary on domestic and international business performance, R&D pipeline, and future outlook contributed to the positive sentiment.
Emcure Pharmaceuticals Limited announced the release of the transcript for their Q2 FY27 Earnings Call, which was held on November 3, 2026. The call featured management participants including Mr. Satish Mehta (Chairman, MD & CEO), Mr. Tajuddin Shaikh (CFO), and others.
During the call, Mr. Satish Mehta reported a strong quarter with revenue growth of 24% year-on-year to ₹2,820 crores, driven by broad-based growth across geographies. EBITDA rose by 31% to ₹575 crores, with EBITDA margins expanding to 20.4%. Profit after tax increased by 29% to ₹325 crores.
The domestic business grew by 12% year-on-year to ₹1,155 crores, with Women's health, cardiometabolic, and CNS portfolios being key drivers. The international business saw robust growth of 34.5% year-on-year to ₹1,665 crores, accounting for 59% of total revenue. Europe grew by 36%, Canada by 24%, and emerging markets (Rest of World) by 41%.
R&D investments were ₹111 crores (4% of revenue), with over 20 product approvals received during the quarter. The company raised its full-year FY27 revenue growth outlook to exceed 20%, up from mid-teens, and expects EBITDA margin improvement at the upper end of its 75-100 basis points guidance.
The CFO, Mr. Tajuddin Shaikh, provided further financial details, including a PAT margin of 11.5% and a net debt of ₹1,317 crores as of September 2026. The company remains committed to becoming net cash by the end of FY28.
Key discussions also included the performance of specific products like liposomal amphotericin B and treprostinil in Europe, the growth trajectory of the domestic business and Zuventus, and the outlook for international markets. The amalgamation of Zuventus Healthcare and Emcutix Biopharmaceuticals into Emcure was also mentioned as a step towards simplifying the group structure.
What to do with a filing like this
Emcure Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Emcure Pharmaceuticals Limited. Read the original for the full detail.